Mr. Wayne Maddever reports

CHROMEDX ANNOUNCES HEMOPALM TRADEMARK AND INTELLECTUAL PROPERTY UPDATE

The U.S. Patent and Trademark Office has allowed a trademark for ChroMedX Corp.'s patented HemoPalm technology, and the trademark will be officially registered when the HemoPalm is released commercially.

The HemoPalm technology is currently covered by two issued and one pending patent. The pending patent will be filed internationally in spring 2015, with the intent to extend the patent protection term in the United States, and to seek patent protection at least in Europe and Asia for the extended term.

"ChroMedX continues to build on a strong foundation of intellectual property detailing the company's novel in vitro diagnostic and point-of-care testing systems. We are pleased to make this announcement and look forward to the official registration of the HemoPalm trademark," said Dr. Wayne Maddever, PEng, president and chief executive officer of ChroMedX.

Furthermore, ChroMedX has recently been assigned U.S. patent 7,807,450 which covers various aspects of the company's plasma extraction cartridge, a novel device for the separation of plasma from whole blood at the point of collection.

The AUF (automatic ultrafiltration) patent application was filed internationally and earlier this year a very favourable written response was issued by the international searching authority. Last week on behalf of ChroMedX, the IP law firm Bereskin & Parr filed a demand for international preliminary examination.

A list of issued and pending patents can be found on the company's website.

We seek Safe Harbor.